Waters Corporation
Waters Corporation provides analytical workflow solutions through two segments: Waters and TA. It designs and manufactures high-performance liquid chromatography and mass spectrometry technology systems. Products include chromatography columns, consumables, and software-based products that interface with its instruments or others. Instruments are used in drug discovery, disease analysis, nutritional safety testing, environmental monitoring, and industrial applications. The company also offers thermal analysis, rheometry, and calorimetry instruments for predicting chemical suitability and stability. Its products serve clinical, pharmaceutical, biochemical, industrial, and academic customers globally.
Overview
Strengths
- Shows the financial signature of a durable competitive advantage (economic moat): consistently high returns on capital, returns well above its cost of capital, high, stable gross margins (pricing power) and operating margins that held up every year.
- Return on invested capital has stayed above 15% in each of the last 6 years (latest 16.4%), a hallmark of a durable competitive advantage.
- Creates economic value: ROIC of 16.4% against a cost of capital (WACC) of 8.4%, a spread of 8.1 percentage points.
- Pricing power: gross margin has held between 57% and 60% over the last 6 years (latest 59.3%).
- EBITDA margin of 32.6% beats 80% of its 30 Diagnostics & Research peers (median 18.7%).
- Conservative leverage: net debt is only 0.8x EBITDA.
Weaknesses
- Eroding returns: ROIC has fallen to 16.4% from a multi-year average of 26.7%, a possible sign of a weakening moat.
- Our discounted cash flow target price (143.83 USD) is 68% below the current price.
- Valued at a premium to its Diagnostics & Research peers: P/FCF 50.0x vs. a median of 24.1x and EV/EBITDA 27.0x vs. a median of 15.5x.
- More expensive than its own history: P/E 42.0x vs. a historical average of 29.5x.
Key Financial Data